Medicaid generic drug reimbursement caps recommended for all products in HHS IG report.
Executive Summary
MEDICAID GENERIC REIMBURSEMENT CAP COULD SAVE $133 MIL. OVER TWO YEARS, the HHS Inspector General suggested in an Aug. 4 report on "Medicaid Pharmacy: Actual Acquisition Cost of Generic Prescription Drug Products." Based on price data for the top 200 generic products reimbursed by Medicaid, the HHS IG found that states paid an estimated $145 mil. more than the cost of the drugs. Of that total, $132.7 mil. was attributable to drugs that do not have an upper limit for Medicaid reimbursement.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth